A Phase 1 interventional study of Radiprodil and Placebo in GRIN-related Neurodevelopmental Disorder Caused by Variants Characterized as Non-Gain-of-Function, sponsored by GRIN Therapeutics, Inc.. Not yet recruiting. Open to participants aged 1 Month to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by GRIN Therapeutics, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a multinational, multicenter, randomized, double-blinded, placebo-controlled, Phase 1b study with an open-label extension (OLE) to assess safety, tolerability, PK, and potential efficacy of radiprodil for the treatment of GRIN-related neurodevelopmental disorder (GRIN-NDD) in children with a genetic variant characterized as non-gain-of-function.
This study will consist of Part A (blinded, placebo-controlled) and Part B (blinded transition followed by an OLE).
Participants will be randomized in a 2:1 ratio to receive active drug (radiprodil) or matching placebo (Part A) and stratified by functional characterization (either indeterminant, LoF, or no effect). Following completion of Part A, all eligible participants (including those previously on placebo) may continue into the open-label extension period (Part B) to receive radiprodil.
The placebo-controlled portion is expected to be approximately 17 weeks for participants in Part A and at least 12 months for participants in Part B.
Participants are assigned in a 2:1 ratio to receive either radiprodil or placebo during Part A with the opportunity to receive radiprodil in the Part B OLE.
This study is divided into the following parts:
Part A: Randomized, double-blind, placebo-controlled
Part B: Open-label safety follow-up period
GRIN Therapeutics, Inc. is the lead sponsor of 8 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Part A, Participant:
Part B, Participant:
- Has completed Part A and is eligible to continue study participation according to the judgment of the Investigator and Sponsor.
Exclusion Criteria:
PART A, Participant:
Part B Participant:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Liquid suspension of radiprodil, at varying concentrations depending on participant's weight. The following dose-escalation regimen (twice daily \[BID\]) will be used: Titration Period Visit 1 (Visit T1): Dose 1, Visit T2: Dose 2, Visit T3: Dose 3, Visit T4: Maintenance Dose.
Drug: Radiprodil
Liquid suspension of placebo matching radiprodil oral suspension and dose-escalation regimen.
Drug: Placebo
Radiprodil oral suspension
Placebo-to-match radiprodil oral suspension
Adverse Events (AEs)
Number and percentage of participants experiencing adverse events (AEs). AEs will be assessed by frequency, type, severity, and duration. Treatment-emergent AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) and summarized by System Organ Class and Preferred Term.
Time frame: From Screening through study completion, including Part A (approximately 17 weeks), Part B (anticipated at least 12 months), and follow-up (14 [+7] days after the last dose including taper or End of Study Visit, whichever is later).
Serious Adverse Events (SAEs)
Number and percentage of participants experiencing serious adverse events (SAEs). SAEs will be assessed by frequency, type, severity, and duration, including treatment-emergent SAEs and SAEs considered related to investigational product.
Time frame: From Screening through study completion, including Part A (approximately 17 weeks), Part B (anticipated at least 12 months), and follow-up (14 [+7] days after the last dose including taper or End of Study Visit, whichever is later).
Adverse Drug Reactions (ADRs)
Number and percentage of participants experiencing adverse drug reactions (ADRs). ADRs will be assessed by frequency, type, severity, and duration and summarized by functional characterization, study part, and overall.
Time frame: From Screening through study completion, including Part A (approximately 17 weeks), Part B (anticipated at least 12 months), and follow-up (14 [+7] days after the last dose including taper or End of Study Visit, whichever is later).
Change From Baseline in Blood Pressure
Change from Baseline in blood pressure (mmHg), assessed at scheduled study visits. Observed values and changes from Baseline will be summarized using descriptive statistics.
Time frame: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
Change From Baseline in Pulse Rate
Change from Baseline in pulse rate (beats per minute), assessed at scheduled study visits. Observed values and changes from Baseline will be summarized using descriptive statistics.
Time frame: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
Physical Examination Findings
Number and percentage of participants with abnormal physical or neurological examination findings. Findings will be listed, and findings indicative of adverse events will be included in adverse event summaries.
Time frame: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
Change From Baseline in ECG Pulse Rate
Change from Baseline in pulse rate measured by 12-lead electrocardiogram (ECG), expressed in beats per minute (bpm).
Time frame: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
Change From Baseline in ECG RR Interval
Change from Baseline in the RR interval measured by 12-lead electrocardiogram (ECG), expressed in milliseconds (ms).
Time frame: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
Change From Baseline in ECG PR Interval
Change from Baseline in the PR interval measured by 12-lead electrocardiogram (ECG), expressed in milliseconds (ms).
Time frame: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
Change From Baseline in ECG QRS Duration
Change from Baseline in QRS duration measured by 12-lead electrocardiogram (ECG), expressed in milliseconds (ms).
Time frame: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
Change From Baseline in ECG QT Interval
Change from Baseline in the QT interval measured by 12-lead electrocardiogram (ECG), expressed in milliseconds (ms).
Time frame: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
Change From Baseline in ECG QTcF Interval
Change from Baseline in the QT interval corrected using Fridericia's formula (QTcF), measured by 12-lead electrocardiogram (ECG), expressed in milliseconds (ms).
Time frame: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
Clinically Significant Changes in Clinical Laboratory Parameters
Number and percentage of participants with clinically significant abnormalities or changes in clinical laboratory parameters, including hematology, serum chemistry, and coagulation assessments. Laboratory values and changes from Baseline will be summarized, and clinically significant abnormal values listed separately.
Time frame: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
Emergence of New Seizure Types
Number and percentage of participants experiencing new seizure types compared with Baseline. Emergence of new seizure types will be tabulated overall and by seizure type at scheduled assessments.
Time frame: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
Occurrence of Suicidal Ideation
Number and percentage of participants experiencing suicidal ideation at any post-Baseline assessment, based on the Columbia-Suicide Severity Rating Scale (C-SSRS) or investigator assessment, as appropriate for the participant.
Time frame: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
Occurrence of Suicidal Behavior
Number and percentage of participants experiencing suicidal behavior at any post-Baseline assessment, based on the Columbia-Suicide Severity Rating Scale (C-SSRS) or investigator assessment, as appropriate for the participant.
Time frame: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
Plasma Concentration of Radiprodil
Plasma concentrations of radiprodil will be measured at predefined pharmacokinetic (PK) sampling timepoints.
Time frame: From first dose through study completion, including Part A (12 weeks of treatment) and Part B (anticipated at least 12 months).
Change From Baseline in SERIAS Green Light Days
Change from Baseline to the end of the Part A Maintenance Period in the number of green light days, assessed using the Seizure-Related Impact Assessment Scale (SERIAS) and captured in the daily electronic diary (eDiary).
Time frame: Baseline (4-week Observation Period) to the end of Part A Maintenance Period (Week 8).
Change From Baseline in SERIAS Yellow Light Days
Change from Baseline to the end of the Part A Maintenance Period in the number of yellow light days, assessed using SERIAS and captured in the daily eDiary.
Time frame: Baseline (4-week Observation Period) to the end of Part A Maintenance Period (Week 8).
Change From Baseline in SERIAS Red Light Days
Change from Baseline to the end of the Part A Maintenance Period in the number of red light days, assessed using SERIAS and captured in the daily eDiary.
Time frame: Baseline (4-week Observation Period) to the end of Part A Maintenance Period (Week 8).
Change From Baseline in Total Countable Seizure Frequency per 28 Days
Change from Baseline in total countable seizure frequency normalized to 28 days during the Part A Maintenance Period (Weeks 1 through 8), as recorded in the daily seizure eDiary.
Time frame: Baseline (last 4 weeks before randomization) through Part A Maintenance Period (8 weeks).
Change From Baseline in EEG Spike Rate
Change from Baseline in electroencephalogram (EEG) spike rate, expressed as spikes per hour, during the Part A Maintenance Period.
Time frame: Baseline through Part A Maintenance Period (Weeks 1 through 8).
Change From Baseline in EEG Background Activity
Change from Baseline in electroencephalogram (EEG) background activity during the Part A Maintenance Period.
Time frame: Baseline through Part A Maintenance Period (Weeks 1 through 8).
Percentage of Participants With at Least 50% Reduction in Total Countable Seizure Frequency
Percentage of participants achieving at least a 50% reduction in total countable seizure frequency per 28 days from Baseline (the last 4 weeks before randomization) to the entire Part A Maintenance Period.
Time frame: Baseline (last 4 weeks before randomization) to the end of Part A Maintenance Period (8 weeks).
Percentage of Participants With at Least 50% Reduction in Total Seizure Frequency
Percentage of participants achieving at least a 50% reduction in total seizure frequency compared with Baseline.
Time frame: Baseline through Part A and Part B, as assessed.
Percent Change From Baseline in Total Countable Seizure Frequency
Percent change from Baseline in total countable seizure frequency normalized to 28 days. Percent change is calculated relative to the Baseline seizure frequency.
Time frame: Baseline through Part A and Part B, as assessed.
Proportion of Seizure-Free Days
Proportion of days without seizures during the assessment period, based on seizure data recorded in the daily eDiary.
Time frame: Baseline through Part A and Part B, as assessed.
Longest Interval of Seizure Freedom
Longest consecutive interval without seizures during the assessment period, based on seizure data recorded in the daily eDiary.
Time frame: Baseline through Part A and Part B, as assessed.
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Oct 2027, 10 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
GRIN Therapeutics, Inc.